BioRegenx, Inc.

What they do

BioRegenx develops and manufactures medical test equipment and science-based nutritional products and distributes wellness devices. Products are sold nationally through a direct selling channel and to health professionals and research organizations. Its consolidated group includes Microvascular Health Services, LLC, My Body Rx, LLC, NuLife Sciences, Inc., and DocSun BioMedical Holdings, Inc., acquired January 8, 2024. It was formed as the surviving company of a March 8, 2024 merger in which the former BioRegenx, Inc. was the accounting acquirer.

Revenue drivers

• Nutritional supplements and wellness products — The historical core business, sold through a direct selling channel and to health professionals; net sales were $1,854,513 for the year ended December 31, 2025, down 21% versus net sales of $2,340,106 in 2024.
• Medical test equipment / wellness devices — Manufactured medical test equipment and wellness devices sold through the same direct selling, health professional, and research organization channels; the 10-Q attributes first-quarter 2026 sales decline to product issues with the medical testing machine.
• DocSun AI diagnostic technology — DocSun, acquired January 8, 2024 in exchange for 76,800,000 common shares, is developing an AI engine combining ballistocardiography, photoplethysmography, and optical coherence tomography for non-invasive vital sign estimation and facial-scanning health monitoring; no significant revenue is disclosed.

Recent performance

First-quarter 2026 net sales were $426,175 compared with $515,147 a year earlier, a 17% decline that management attributes to product issues with the medical testing machine and their effect on the distributor base and nutritional sales. Cost of sales fell 29% to $77,887, yielding gross profit of $348,288 versus $406,031. Total operating expenses fell 34% to $398,052, producing an operating loss of $49,764 versus $192,615. Other income of $100,435 and interest and financing costs of $77,086 produced a net loss of $26,415, versus $266,854 a year earlier. For full-year 2025 gross sales were $1,862,543, with returns of $8,030, and net sales fell 21% from $2,340,106 in 2024.

Strategy

The company is attempting to commercialize a portfolio that spans dietary supplements, medical devices, software, and contactless diagnostic technology, supported by ongoing clinical studies the 10-K says may not demonstrate efficacy or regulatory acceptance. DocSun's engineering team is installing new hardware and coding software to enhance AI capabilities. The company has engaged in multiple acquisitions, including DocSun, and expansion into telehealth, wellness, and diagnostics. A previously agreed up-to-1-for-25 reverse split intended to attract institutional investors and support graduating to OTCQB or NASDAQ has not occurred as of the 10-K filing. Management states it will need substantial capital to fund working capital and pursue its current plans.

Risks

• Going concern and negative equity — As of March 31, 2026 the company had $45,806 of cash, total liabilities of $4.9 million against total assets of $337,070, and shareholder equity of negative $4.5 million.
• Revenue concentration in a shrinking channel — Net sales fell from $2,340,106 in 2024 to $1,854,513 in 2025 and to $426,175 in Q1 2026 from $515,147, with management tying the decline to product issues with the medical testing machine and their effects on the distributor base.
• Regulatory and clinical uncertainty — The company's device, software, and contactless diagnostic offerings face FDA registration, listing, labeling, quality system, and possible premarket review, and the 10-K states clinical studies may not demonstrate efficacy or support regulatory acceptance; supplement claims have not been evaluated by the FDA.
• Control, dilution, and disclosure history — The March 2024 merger exchanged former BioRegenx shares for 851,977,296 common shares and 3,800 Series A preferred shares representing 90.0% of voting securities, and the company filed 8-Ks on May 16 and June 11, 2024 indicating it changed accountants and that previously issued financials were not reliable.

Outlook

Management states the company is a smaller reporting company that has incurred substantial losses and will need substantial capital to fund working capital and pursue its plans. No specific revenue, earnings, or financing commitments are disclosed in the excerpts provided. The previously agreed reverse split, intended to support an OTCQB or NASDAQ graduation, remains unconsummated as of the 10-K.